CA3237463A1 - Novel peptides - Google Patents
Novel peptides Download PDFInfo
- Publication number
- CA3237463A1 CA3237463A1 CA3237463A CA3237463A CA3237463A1 CA 3237463 A1 CA3237463 A1 CA 3237463A1 CA 3237463 A CA3237463 A CA 3237463A CA 3237463 A CA3237463 A CA 3237463A CA 3237463 A1 CA3237463 A1 CA 3237463A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- antibody
- light chain
- heavy chain
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2115925.6 | 2021-11-05 | ||
| GB202115925 | 2021-11-05 | ||
| GB2204539.7 | 2022-03-30 | ||
| GBGB2204539.7A GB202204539D0 (en) | 2022-03-30 | 2022-03-30 | Novel peptides |
| GBGB2212801.1A GB202212801D0 (en) | 2022-09-02 | 2022-09-02 | Novel peptides |
| GB2212801.1 | 2022-09-02 | ||
| PCT/EP2022/080861 WO2023079102A2 (en) | 2021-11-05 | 2022-11-04 | Novel peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3237463A1 true CA3237463A1 (en) | 2023-05-11 |
Family
ID=84329469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3237463A Pending CA3237463A1 (en) | 2021-11-05 | 2022-11-04 | Novel peptides |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20260001961A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4426733A2 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024542142A (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240099410A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022381977A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3237463A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312556A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024005508A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2023079102A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260001961A1 (en) * | 2021-11-05 | 2026-01-01 | Alligator Bioscience Ab | Novel polypeptides |
| JP2026515781A (ja) * | 2023-04-13 | 2026-05-19 | アリゲーター・バイオサイエンス・アーベー | 併用療法 |
| CN117924468B (zh) * | 2023-12-08 | 2024-09-20 | 南京大学 | 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| LT2691417T (lt) | 2011-03-29 | 2018-10-25 | Roche Glycart Ag | Antikūno fc variantai |
| GB201115280D0 (en) * | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| CA2980189A1 (en) * | 2015-04-24 | 2016-10-27 | Genentech, Inc. | Multispecific antigen-binding proteins |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| EP3898681A2 (en) * | 2018-12-17 | 2021-10-27 | Alligator Bioscience AB | Polypeptides |
| GB201820556D0 (en) | 2018-12-17 | 2019-01-30 | Alligator Bioscience Ab | Novel polypeptides |
| AU2020357944A1 (en) * | 2019-09-30 | 2022-03-31 | Adimab, Llc | CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same |
| EP4048701A4 (en) | 2019-10-23 | 2024-05-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| KR20220147583A (ko) * | 2020-01-09 | 2022-11-03 | 바이오뮤넥스 파마슈티컬스 | Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체 |
| US20260001961A1 (en) * | 2021-11-05 | 2026-01-01 | Alligator Bioscience Ab | Novel polypeptides |
-
2022
- 2022-11-04 US US18/703,623 patent/US20260001961A1/en active Pending
- 2022-11-04 IL IL312556A patent/IL312556A/en unknown
- 2022-11-04 WO PCT/EP2022/080861 patent/WO2023079102A2/en not_active Ceased
- 2022-11-04 CA CA3237463A patent/CA3237463A1/en active Pending
- 2022-11-04 MX MX2024005508A patent/MX2024005508A/es unknown
- 2022-11-04 KR KR1020247018489A patent/KR20240099410A/ko active Pending
- 2022-11-04 JP JP2024526902A patent/JP2024542142A/ja active Pending
- 2022-11-04 EP EP22800717.5A patent/EP4426733A2/en active Pending
- 2022-11-04 EP EP22822279.0A patent/EP4426738A2/en active Pending
- 2022-11-04 US US17/980,751 patent/US11873348B2/en active Active
- 2022-11-04 AU AU2022381977A patent/AU2022381977A1/en active Pending
- 2022-11-04 WO PCT/EP2022/080860 patent/WO2023079101A2/en not_active Ceased
- 2022-11-04 JP JP2024526901A patent/JP2024543043A/ja active Pending
- 2022-11-04 KR KR1020247018934A patent/KR20240114794A/ko active Pending
-
2023
- 2023-11-13 US US18/507,736 patent/US12448465B2/en active Active
-
2025
- 2025-09-15 US US19/329,496 patent/US20260146107A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024542142A (ja) | 2024-11-13 |
| WO2023079101A3 (en) | 2023-06-15 |
| JP2024543043A (ja) | 2024-11-19 |
| IL312556A (en) | 2024-07-01 |
| US20260001961A1 (en) | 2026-01-01 |
| KR20240099410A (ko) | 2024-06-28 |
| AU2022381977A1 (en) | 2024-05-23 |
| KR20240114794A (ko) | 2024-07-24 |
| US11873348B2 (en) | 2024-01-16 |
| EP4426738A2 (en) | 2024-09-11 |
| US20260146107A1 (en) | 2026-05-28 |
| WO2023079101A2 (en) | 2023-05-11 |
| EP4426733A2 (en) | 2024-09-11 |
| US20240117074A1 (en) | 2024-04-11 |
| US12448465B2 (en) | 2025-10-21 |
| US20230312754A1 (en) | 2023-10-05 |
| MX2024005508A (es) | 2024-09-18 |
| WO2023079102A2 (en) | 2023-05-11 |
| WO2023079102A3 (en) | 2023-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12173082B2 (en) | Bispecific polypeptides against CD137 | |
| US12202870B2 (en) | Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof | |
| US11713356B2 (en) | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer | |
| US20190016771A1 (en) | Trimeric costimulatory tnf family ligand-containing antigen binding molecules | |
| US20190161555A1 (en) | Bispecific Antibodies Directed Against OX40 and a Tumor-Associated Antigen | |
| JP2022017275A (ja) | Cd40およびfapに特異的に結合することができる新規な二重特異性抗原結合分子 | |
| US12448465B2 (en) | Peptides | |
| US20220073635A1 (en) | Novel polypeptides | |
| US20220064325A1 (en) | Novel polypeptides | |
| WO2024213533A1 (en) | Combination therapies | |
| CN118556080A (zh) | 新型肽 | |
| HK40004686B (en) | Novel bispecific polypeptides against cd137 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241030 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241030 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241030 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST TO REGISTER A DOCUMENT RECEIVED Effective date: 20241112 Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241112 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251020 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251020 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REGISTER A DOCUMENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260415 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260601 |